Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220621 | 0.92 | POLB (0.46) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7800974 | 0.87 | MEN1 (0.45) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL686083 | 0.84 | POLB (0.41) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL10633351 | 0.84 | MEN1 (0.58) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL18622113 | 0.82 | POLB (0.57) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL8139448 | 0.81 | POLB (0.44) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL25868825 | 0.81 | MEN1 (0.47) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL10172327 | 0.81 | MEN1 (0.47) | EPHX1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL15981919 | 0.81 | ADRA1A (0.62) | MEN1KMT2APOLBADRA1AMAPK1 | |
| SCHEMBL24376776 | 0.80 | EPHX1 (0.68) | EPHX1MEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | PNKP, ADAR, NCL | EPHX1 3653/4885MEN1 4273/4885KMT2A 1178/4885 |
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | CD63, NSF, MSN | EPHX1 1065/4885MEN1 2408/4885KMT2A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.